Tizveni

Tizveni is a cancer medicine for non-small cell lung cancer (NSCLC). It is used in adults to treat: - non-squamous NSCLC, in combination with pemetrexed (a chemotherapy medicine that kills cells that are dividing, such as cancer cells) and cisplatin or carboplatin (other chemotherapy medicines), when the disease is metastatic (meaning it has spread to other parts of the body) or when the tumour is locally advanced (meaning it has spread into tissues around the lungs but not to other parts of the body) and cannot be treated with surgery or platinum-based medicines. It is used when at least 50% of the tumour cells have the protein PD-L1 on their surface and the cancer has no mutations (changes) in the EGFR and ALK genes; - squamous NSCLC, in combination with carboplatin and paclitaxel or nab-paclitaxel (other cancer medicines), when the disease is metastatic or when the tumour is locally advanced and cannot be treated with surgery or platinum-based medicines; - NSCLC that is locally advanced or metastatic, when cancer treatment with platinum-based medicines has not worked well enough. In these patients, Tizveni is used on its own. Patients whose cancer has an EGFR or ALK mutation should also have received medicines that target these mutations before starting Tizveni. Tizveni contains the active substance tislelizumab.